Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAT-SchA@SCM
- Development stage
- Preclinical
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CAT-SchA@SCM is a biomimetic nanoparticle drug delivery system designed to ameliorate cytoxan (cyclophosphamide)-induced testicular injury and preserve male fertility. Developed by researchers at Nanjing University and Nanjing Drum Tower Hospital, the system consists of catalase (CAT) protein nanoparticles loaded with schisandrin A (SchA), a bioactive compound derived from *Schisandra chinensis* that mimics superoxide dismutase (SOD) activity. To overcome the blood-testis barrier (BTB) and enable targeted delivery, the nanoparticles are encapsulated in TM4 (Sertoli-like) cell membranes (SCM). CAT-SchA@SCM acts by scavenging reactive oxygen species (ROS), inhibiting apoptosis, and activating the Nrf2-HO-1 antioxidant signaling pathway, thereby protecting Sertoli cells and restoring testicular function, sperm motility, and testosterone levels.
- Other names
- Sertoli cell membrane-modified schisandrin A-loaded catalase nanoparticlestesticular Sertoli cell membrane-modified schisandrin A-loaded catalase nanoparticles
02
Targets
HMOX1 (Heme oxygenase 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on CAT-SchA@SCM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAT-SchA@SCM.